VERA vs. DYN, GLPG, PTCT, MRVI, AMPH, NAMS, JANX, RYTM, KROS, and TGTX
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Dyne Therapeutics (DYN), Galapagos (GLPG), PTC Therapeutics (PTCT), Maravai LifeSciences (MRVI), Amphastar Pharmaceuticals (AMPH), NewAmsterdam Pharma (NAMS), Janux Therapeutics (JANX), Rhythm Pharmaceuticals (RYTM), Keros Therapeutics (KROS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical preparations" industry.
Vera Therapeutics (NASDAQ:VERA) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 22.6% of Vera Therapeutics shares are owned by company insiders. Comparatively, 32.9% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Vera Therapeutics had 5 more articles in the media than Dyne Therapeutics. MarketBeat recorded 20 mentions for Vera Therapeutics and 15 mentions for Dyne Therapeutics. Vera Therapeutics' average media sentiment score of 0.49 beat Dyne Therapeutics' score of 0.45 indicating that Vera Therapeutics is being referred to more favorably in the media.
Vera Therapeutics received 11 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 64.71% of users gave Dyne Therapeutics an outperform vote while only 52.38% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Vera Therapeutics presently has a consensus price target of $32.29, indicating a potential downside of 26.34%. Dyne Therapeutics has a consensus price target of $37.43, indicating a potential upside of 31.33%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Vera Therapeutics.
Vera Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vera Therapeutics' return on equity of -68.25% beat Dyne Therapeutics' return on equity.
Summary
Vera Therapeutics beats Dyne Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vera Therapeutics Competitors List
Related Companies and Tools